Insilico's AI-discovered lung fibrosis drug enters Phase III
Rentosertib will test whether Insilico's end-to-end AI drug discovery thesis can survive late-stage clinical scrutiny.
Read the full articleYou might also wanna read
Insilico Medicine advances AI drug for IPF to Phase III trials
Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF).
How Will AI Transform the Future of Drug Discovery? AI Brings New Hope for Drug Development
Explore how AI is revolutionizing drug discovery, reducing costs, and accelerating treatment development for complex diseases like idiopathi
Takeda signs $600M AI drug discovery deal with Insilico
Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japan
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
Conditions : Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF) Interventions : Drug: Nintedanib Dry Powder Inhalation; Drug
New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'
For a long time, the likelihood of surviving pancreatic cancer has been extremely low.
sciencealert.com·1mo agoIonis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across
Comments
Sign in to join the conversation.
No comments yet. Be the first.